Advances in Ketogenic Diet Therapies in Pediatric Epilepsy: A Systematic Review

Dilshad Parveen1, Vidisha Jain2, Dhivya Kannan3

  • 1Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, India.

Insights

The ketogenic diet effectively reduces seizure frequency and severity in children and adolescents with epilepsy. While side effects are manageable, its success depends on patient adherence and existing health conditions.

Area of Science:

  • Neurology
  • Pediatric Medicine
  • Nutritional Science

Background:

  • Epilepsy is a neurological disorder affecting children and adolescents, often requiring diverse treatment strategies.
  • The ketogenic diet, a high-fat, low-carbohydrate regimen, has emerged as a potential therapeutic option for drug-resistant epilepsy.

Approach:

  • A systematic literature search was performed using PubMed, adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
  • Included studies focused on children and adolescents with epilepsy, analyzing various ketogenic diet formulations and their impact on seizure control.
  • Twelve studies meeting specific inclusion criteria were selected for data extraction on study design, duration, sample size, population, and intervention type.

Key Points:

  • The ketogenic diet and its modified versions demonstrated significant benefits in reducing seizure frequency and severity in pediatric epilepsy patients.
  • Commonly observed adverse effects included gastrointestinal disturbances, dehydration, dyslipidemia, hyperuricemia, infection, and metabolic acidosis, which were generally manageable.
  • Variations of the ketogenic diet proved effective as both adjunctive and alternative treatments for epilepsy in this population.

Conclusions:

  • The ketogenic diet is a viable treatment option for managing epilepsy in children and adolescents, offering seizure reduction benefits.
  • Treatment success and tolerability are influenced by individual patient compliance and the presence of comorbidities.
  • Further research may explore optimizing ketogenic diet protocols to maximize efficacy and minimize adverse events in pediatric epilepsy.

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
317
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
186
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
382
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
168
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
285
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
31